Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Mizuho analyst Graig Suvannavejh maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Buy and lowers the price target fro...
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate...
-SEC Filing
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quart...
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday.
Adaptimmune Therapeutics (NASDAQ:ADAP) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate...
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...
